AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36378622 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from biopsy to integrated histological-molecular diagnosis using whole-genome sequencing and epigenomic classification
Number of subjects: 1000
Study 36378622 — intervention group
Group type: EXPERIMENTAL
Intervention: Process centred, patient centred and framework based measures
Number of subjects: 1000
Study 36378673 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI stage B
Number of subjects: 237
Study 36378673 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI stage C
Number of subjects: 237
Study 36378673 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI stage D
Number of subjects: 237
Study 36378673 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI stage E
Number of subjects: 237
Study 36378673 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI classification at 24-h
Number of subjects: 237
Study 36378678 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL system (Edwards Lifesciences)
Number of subjects: 74
Study 36378741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion-specific IVUS-FFR ≤0.95
Number of subjects: 697
Study 36378741 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 697
Study 36378758 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-disadvantage quintiles
Number of subjects: 593053
Study 36378770 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aids (DAs) for shared decision making (SDM)
Number of subjects: 22
Study 36378770 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of DAs
Number of subjects: 22
Study 36378770 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS mandate for SDM
Number of subjects: 22
Study 36378770 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician support for DAs
Number of subjects: 22
Study 36378814 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet Pressure Support
Number of subjects: 0
Study 36378814 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 36378814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal High-Flow
Number of subjects: 0
Study 36378864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost Implant
Number of subjects: 0
Study 36378864 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 36379002 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg intravenously once every 3 weeks
Number of subjects: 45
Study 36379002 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 45
Study 36379575 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) withdrawal after achieving inactive disease for 40 weeks
Number of subjects: 112
Study 36379575 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) retreatment for 12 weeks
Number of subjects: 112
Study 36379575 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics (absence of MRI sacroiliitis and hs-CRP > 3 mg/L)
Number of subjects: 112
Study 36379575 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex and age younger than 40 years
Number of subjects: 112
Study 36379595 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cytoreductive surgery (≥5 cycles of chemotherapy)
Number of subjects: 1000
Study 36379595 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (after 3-4 cycles of chemotherapy)
Number of subjects: 1000
Study 36379595 — intervention group
Group type: COMPARATOR
Intervention: No surgery (≥5 cycles of chemotherapy alone)
Number of subjects: 1000
Study 36379595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1000
Study 36379595 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 1000
Study 36379595 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators/barriers to prevalent practice and access to cytoreductive surgery
Number of subjects: 1000
Study 36379650 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination knowledge, beliefs, and attitudes assessment through one-on-one interviews
Number of subjects: 45
Study 36379650 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mainstream media and top-down health education activities
Number of subjects: 45
Study 36379650 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of local community health workers and established community social and leadership structures
Number of subjects: 45
Study 36379649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurturing care and health determinants
Number of subjects: 5054
Study 36379649 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical differences and disparities in healthcare
Number of subjects: 5054
Study 36379649 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving routines
Number of subjects: 5054
Study 36379665 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns reported by parents, teachers, and nurses regarding children's well-being.
Number of subjects: 1341
Study 36379665 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding growth and/or physical symptoms.
Number of subjects: 1341
Study 36379665 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding emotions.
Number of subjects: 1341
Study 36379665 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding concentration.
Number of subjects: 1341
Study 36379665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall concerns leading to school doctor actions.
Number of subjects: 1341
Study 36379880 — intervention group
Group type: EXPERIMENTAL
Intervention: R-chemotherapy
Number of subjects: 1202
Study 36379880 — intervention group
Group type: EXPERIMENTAL
Intervention: G-chemotherapy
Number of subjects: 1202
Study 36380152 — intervention group
Group type: EXPERIMENTAL
Intervention: RadioFrequency Ablation (RFA)
Number of subjects: 48
Study 36380152 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 48
Study 36380155 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided Histotripsy
Number of subjects: 45
Study 36380774 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study 36380774 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement
Number of subjects: 0
Study 36381503 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine during ongoing siponimod treatment (cohort 1)
Number of subjects: 41
Study 36381503 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine during siponimod treatment interruption (cohort 2)
Number of subjects: 41
Study 36381503 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine while on other DMTs or no therapy (cohort 3)
Number of subjects: 41
Study 36381988 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-based artificial intelligence screening
Number of subjects: 200
Study 36381988 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-based screening in primary care
Number of subjects: 200
Study 36381988 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-based amyloid pre-screening
Number of subjects: 200
Study 36382108 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg, orally administered, scaled by body weight)
Number of subjects: 22
Study 36382109 — intervention group
Group type: EXPERIMENTAL
Intervention: Trotabresib 15, 30, and 45 mg combined with TMZ in the adjuvant setting
Number of subjects: 32
Study 36382109 — intervention group
Group type: EXPERIMENTAL
Intervention: Trotabresib 15 and 30 mg combined with TMZ+RT in the concomitant setting
Number of subjects: 32
Study 36382109 — intervention group
Group type: EXPERIMENTAL
Intervention: Trotabresib 30 mg established as the recommended phase II dose (RP2D) in both settings
Number of subjects: 32
Study 36382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1008
Study 36382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium (Gd)+ lesions at baseline
Number of subjects: 1008
Study 36382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline EDSS ≥3.5
Number of subjects: 1008
Study 36382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants (<38 years at baseline)
Number of subjects: 1008
Study 36382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting lesion counts > median (≥71 T2 hyperintense lesions)
Number of subjects: 1008
Study 36382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline T2 lesion volume
Number of subjects: 1008
Study 36382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher T2 volume
Number of subjects: 1008
Study 36382118 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline EDSS <2
Number of subjects: 1008
Study 36382130 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Number of subjects: 20
Study 36382130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 36382554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with ado-trastuzumab emtansine
Number of subjects: 1700
Study 36382554 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with ado-trastuzumab emtansine
Number of subjects: 1700
Study 36382599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-based DAPT
Number of subjects: 2583
Study 36382599 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation to clopidogrel after NB
Number of subjects: 2583
Study 36382599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuisance bleeding (NB)
Number of subjects: 2583
Study 36382911 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid imaging with Carbon-11-Labeled Methionine PET/CT
Number of subjects: 7
Study 36382956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean corCSA measured by noncontrast computed tomography
Number of subjects: 105
Study 36383021 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (inactivated vaccine)
Number of subjects: 148
Study 36383213 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of amalgam restorations
Number of subjects: 0
Study 36383294 — intervention group
Group type: EXPERIMENTAL
Intervention: BT595 (10% Human Normal Immunoglobulin) administered at doses between 0.2 and 0.8 g/kg body weight for approximately 12 months at intervals of either 3 or 4 weeks
Number of subjects: 18
Study 36383511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with school-aged children
Number of subjects: 848
Study 36383511 — intervention group
Group type: COMPARATOR
Intervention: Mothers with 2 children
Number of subjects: 848
Study 36383511 — intervention group
Group type: COMPARATOR
Intervention: Mothers with 2 children (school-aged)
Number of subjects: 848
Study 36383511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with 2 children (≤4y)
Number of subjects: 848
Study 36383511 — intervention group
Group type: COMPARATOR
Intervention: Mothers with multiple children and only children aged ≤4y
Number of subjects: 848
Study 36383708 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight participants (weight-for-age z score <-1)
Number of subjects: 0
Study 36383708 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who died during the study
Number of subjects: 0
Study 36383708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis of participants
Number of subjects: 0
Study 36383730 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 103
Study 36383730 — intervention group
Group type: COMPARATOR
Intervention: Prevnar 13 (PCV13)
Number of subjects: 103
Study 36383760 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral care
Number of subjects: 6244
Study 36383760 — intervention group
Group type: COMPARATOR
Intervention: Usual oral care
Number of subjects: 6244
Study 36383907 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled monoclonal antibodies (mAbs)
Number of subjects: 0
Study 36383907 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-drug conjugates (ADCs)
Number of subjects: 0
Study 36384095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inhibition of SHP2 using RMC-4550 and ERK using LY3214996
Number of subjects: 0
Study 36384183 — intervention group
Group type: EXPERIMENTAL
Intervention: FORS-guided procedures
Number of subjects: 82
Study 36384183 — intervention group
Group type: COMPARATOR
Intervention: Non-FORS-guided procedures
Number of subjects: 82
Study 36384393 — intervention group
Group type: EXPERIMENTAL
Intervention: early-PN
Number of subjects: 1212
Study 36384393 — intervention group
Group type: EXPERIMENTAL
Intervention: late-PN
Number of subjects: 1212
Study 36384393 — intervention group
Group type: COMPARATOR
Intervention: matched healthy children
Number of subjects: 1212
Study 36384443 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of insulin-like growth factor-1 (IGF-1)
Number of subjects: 0
Study 36384443 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of IGF-1 binding protein-3 (IGFBP-3)
Number of subjects: 0
Study 36384443 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of GH receptor (GHR)
Number of subjects: 0
Study 36384443 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of GH-binding protein (GHBP)
Number of subjects: 0
Study 36384443 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue (AT) expression
Number of subjects: 0
Study 36384443 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fat mass
Number of subjects: 0
Study 36384465 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a standardized acute KRT pathway including routine monitoring of KPIs and prescriber reports.
Number of subjects: 0
Study 36384465 — intervention group
Group type: COMPARATOR
Intervention: Baseline performance of acute KRT before implementation of the pathway.
Number of subjects: 0
Study 36384544 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified flipped classroom for 6 weeks
Number of subjects: 128
Study 36384544 — intervention group
Group type: COMPARATOR
Intervention: Traditional flipped classrooms
Number of subjects: 128
Study 36384579 — intervention group
Group type: EXPERIMENTAL
Intervention: ChildTalks+ intervention (4 structured psychoeducational sessions)
Number of subjects: 66
Study 36384579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention until after the last assessment)
Number of subjects: 66
Study 36384656 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing TAVI
Number of subjects: 11440
Study 36384656 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treated diabetics
Number of subjects: 11440
Study 36384907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg
Number of subjects: 1286
Study 36384907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1286
Study 36384966 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz, applied to the bilateral dorsolateral prefrontal cortex, 5x/week for 4 weeks)
Number of subjects: 0
Study 36384966 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study 36384966 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 0
Study 36385011 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-lambda treatment
Number of subjects: 0
Study 36385011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36385120 — intervention group
Group type: EXPERIMENTAL
Intervention: CYH33 1-60 mg
Number of subjects: 51
Study 36385136 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum daily precipitation increase (10 cm)
Number of subjects: 0
Study 36385136 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific humidity increase (g/kg)
Number of subjects: 0
Study 36385136 — intervention group
Group type: EXPERIMENTAL
Intervention: High emission assumptions for climate change
Number of subjects: 0
Study 36385536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib 4 mg weekly until progressive disease or unacceptable adverse events.
Number of subjects: 33
Study 36385536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib 4 mg weekly combined with short-course rituximab (4-week course added during month 7).
Number of subjects: 33
Study 36385536 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline downregulation of proteasome genes, PSMB9 and PSMB8.
Number of subjects: 33
Study 36385536 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination.
Number of subjects: 33
Study 36385585 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Number of subjects: 0
Study 36385585 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptations to BPT targeting emotion regulation (ER)
Number of subjects: 0
Study 36386029 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (two or more doses)
Number of subjects: 1005
Study 36386029 — intervention group
Group type: COMPARATOR
Intervention: Surfactant (one or less doses)
Number of subjects: 1005
Study 36386029 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall NARDS incidence
Number of subjects: 1005
Study 36386029 — intervention group
Group type: EXPERIMENTAL
Intervention: Aetiological factors
Number of subjects: 1005
Study 36386029 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD and/or death
Number of subjects: 1005
Study 36386029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidences of NARDS
Number of subjects: 1005
Study 36386039 — intervention group
Group type: COMPARATOR
Intervention: ColonES assay for ctDNA methylation haplotype patterns
Number of subjects: 1138
Study 36386039 — intervention group
Group type: EXPERIMENTAL
Intervention: High preoperative ctDNA methylation levels
Number of subjects: 1138
Study 36386175 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36386307 — intervention group
Group type: EXPERIMENTAL
Intervention: V-PPG measurement during the 'Ca' position
Number of subjects: 424
Study 36386307 — intervention group
Group type: EXPERIMENTAL
Intervention: V-PPG measurement during the 'Pra' position
Number of subjects: 424
Study 36386348 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent acute myocarditis episodes
Number of subjects: 21
Study 36386348 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing
Number of subjects: 21
Study 36386348 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of cardiomyopathy or early sudden cardiac death
Number of subjects: 21
Study 36386357 — intervention group
Group type: EXPERIMENTAL
Intervention: Single transradial guiding catheter (STGC)
Number of subjects: 560
Study 36386357 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 560
Study 36386418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol (Group P)
Number of subjects: 40
Study 36386418 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia with sevoflurane (Group S)
Number of subjects: 40
Study 36386456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus docetaxel
Number of subjects: 137
Study 36386776 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA)
Number of subjects: 30
Study 36386776 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 36386914 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day intermittent fasting (IF) combined with protein pacing (4-5 meals/day, >30% protein/day)
Number of subjects: 0
Study 36386914 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day intermittent fasting (IF) combined with protein pacing (4-5 meals/day, >30% protein/day)
Number of subjects: 0
Study 36386914 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36386926 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) intervention for 2 months
Number of subjects: 0
Study 36386926 — intervention group
Group type: COMPARATOR
Intervention: No time restrictions (control group)
Number of subjects: 0
Study 36386937 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day grape polyphenol extract
Number of subjects: 60
Study 36386937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36386979 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic terminal case vignette
Number of subjects: 20000
Study 36386979 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic non-terminal case vignette
Number of subjects: 20000
Study 36386979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental non-terminal case vignette
Number of subjects: 20000
Study 36386979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical guidelines of the Swiss Medical Association (2004, 2018, 2022)
Number of subjects: 20000
Study 36386979 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigmatization of mentally ill people
Number of subjects: 20000
Study 36386982 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment for 12 weeks
Number of subjects: 13
Study 36387207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiducial markers implantation
Number of subjects: 15
Study 36387835 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 164
Study 36387835 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 164
Study 36387967 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC-15L
Number of subjects: 163
Study 36387967 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 163
Study 36387989 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH Healthy Smiles intervention (classroom curriculum, toothbrushing routine, family outreach, and schoolwide coordinated activities) implemented for three years.
Number of subjects: 1020
Study 36387989 — intervention group
Group type: COMPARATOR
Intervention: Control group offered free trainings and materials to implement a sun safety curriculum.
Number of subjects: 1020
Study 36387991 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetrating needle acupuncture
Number of subjects: 80
Study 36387991 — intervention group
Group type: COMPARATOR
Intervention: Skin-touch placebo needle
Number of subjects: 80
Study 36388001 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Exercise Programme (PEP)
Number of subjects: 367